Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE
Latest news on ALLERGAN PLC
10:22aSOSEI : Allergan to delay trials of dementia candidate
AQ
09/18ALLERGAN : to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics..
AQ
09/17ALLERGAN : Announces Results of Higher Dose BOTOX Cosmetic (onabotulinumtoxinA) ..
AQ
09/17CEL SCI : Botox Effect Lasts Longer At Higher Doses, TEVA Gets FDA Nod, KNSA On ..
AQ
09/15ALLERGAN : to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics..
AQ
09/14ALLERGAN : Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA)..
PR
09/14ALLERGAN : Highlights Key Growth Drivers for Medical Aesthetics
PR
09/14Allergan says revenue from aesthetics unit may double by 2025
RE
09/14ALLERGAN : Unveils Spotlyte, a First-In-Category Digital Hub Designed To Educate..
AQ
09/14ALLERGAN : to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics..
PR
09/13THE MOST EXCITING ADVANCE IN SKINCAR : Introducing the SkinMedica® LUMIVIVE&trad..
AQ
09/12ALLERGAN : Unveils Spotlyte™, A First-In-Category Digital Hub Designed To ..
PR
09/12ALLERGAN : to Host Medical Aesthetics Day Event on September 14, 2018
AQ
09/10ALLERGAN : to Host Medical Aesthetics Day Event on September 14, 2018
PR
09/10ALLERGAN : Most Exciting Advance in Skincare is here, introducing the SkinMedica..
AQ
09/06ALLERGAN : Continues Board Refreshment Process
AQ
09/06ALLERGAN : Trademark Application for "CENTELLINE" Filed by Allergan
AQ
09/06ALLERGAN : to Present at the 2018 Morgan Stanley Global Healthcare Conference
AQ
09/06THE MOST EXCITING ADVANCE IN SKINCAR : Introducing the SkinMedica® LUMIVIVE&trad..
PU
09/04ALLERGAN : Statement of changes in beneficial ownership of securities Basgoz Nes..
PU
09/04ALLERGAN : Statement of changes in beneficial ownership of securities Boccuzi Jo..
PU
09/04ALLERGAN : to Present at the 2018 Morgan Stanley Global Healthcare Conference
PR
08/31ALLERGAN : Continues Board Refreshment Process
AQ
08/30ALLERGAN : Receives Complete Response Letter from the U.S. Food and Drug Adminis..
AQ
08/30ALLERGAN : to Present at the 2018 Wells Fargo Healthcare Conference
PR
08/29ALLERGAN PLC : Change in Directors or Principal Officers (form 8-K)
AQ
08/29ALLERGAN : Continues Board Refreshment Process
PR
08/27Allergan, Mohawk Tribe request rehearing in sovereign immunity IPR case
AQ
08/24ALLERGAN : US FDA seeks additional information from Allergan`s ulipristal acetat..
AQ
08/23ALLERGAN : Receives Complete Response Letter from the U.S. Food and Drug Adminis..
AQ
08/22ALLERGAN : uterine fibroids therapy hits regulatory setback
AQ
08/21ALLERGAN : Receives Complete Response Letter from the U.S. Food and Drug Adminis..
PU
08/21BIOCENTURY - MANAGEMENT TRACKS : Athenex, Intra-Cellular
AQ
08/16ALLERGAN : Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board o..
AQ
08/16ALLERGAN : Trademark Application for "PROJECT MOONWALKER" Filed
AQ
08/16ALLERGAN : Trademark Application for "MOONWALKER" Filed
AQ
08/16ALLERGAN : An Application for the Trademark "WHEN SKINCARE WORKS, YOU KNOW IT'S ..
AQ
08/16ALLERGAN : Trademark Application for "REGI" Filed by Allergan
AQ
08/16ALLERGAN : and Editas Medicine Announce Exercise of Options to Jointly Develop C..
AQ
08/16ALLERGAN : Reports from Allergan Describe Recent Advances in Dermatologic Surger..
AQ
08/16ALLERGAN PLC : Ex-dividend day for
FA
08/14ALLERGAN : Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board o..
AQ
08/14BIOCENTURY - MANAGEMENT TRACKS : FDA, Allergan
AQ
08/10ALLERGAN : and Editas Medicine Announce Exercise of Options to Jointly Develop C..
AQ
08/09ALLERGAN : Trademark Application for "PRESBYSOL" Filed
AQ
08/09ALLERGAN : An Application for the Trademark "BIOCELL" Has Been Filed by Allergan
AQ
08/09ALLERGAN : Reports Outline Pharmaceutical Science Study Results from Allergan (F..
AQ
08/08ALLERGAN : Report of unscheduled material events or corporate event
PU
08/08ALLERGAN PLC : Change in Directors or Principal Officers (form 8-K)
AQ
08/08ALLERGAN : Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board o..
PR
08/03U.S. tax cuts prompt rethink by some 'inverted' companies
RE
08/03ALLERGAN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
08/02ALLERGAN : Announces Third Quarter 2018 Cash Dividend of $0.72 per Ordinary Shar..
AQ
07/31Novartis Gets EU Nod for First-Of-Its-Kind Migraine Drug
DJ
07/31TODAY'S RESEARCH REPORTS ON TRENDING : Bristol-Myers Squibb and Allergan
AC
07/30ALLERGAN : Announces Third Quarter 2018 Cash Dividend of $0.72 Per Ordinary Shar..
PR
07/30Anti-Aging Products And Services Market By Key Participants Allergan Plc, Alm..
AQ
07/28Anti-Aging Products And Services Market By Key Participants Allergan Plc, Alm..
AQ
07/26ALLERGAN : An Application for the Trademark "RAYOPTA" Has Been Filed by Allergan
AQ
07/26ALLERGAN : and Molecular Partners Announce Two Positive Phase 3 Clinical Trials ..
AQ
07/26IRONWOOD PHARMACEUTICALS : Initiates Phase IIIb Study of Linaclotide in Adult Pa..
AQ
07/26ALLERGAN PLC : Results of Operations and Financial Condition, Financial Statemen..
AQ
07/26ALLERGAN : 2Q Earnings Snapshot
AQ
07/26ALLERGAN : Reports Strong Second Quarter 2018 Results Including GAAP Net Revenue..
PR
07/26ALLERGAN : Statement of changes in beneficial ownership of securities
PU
07/24ALLERGAN : receives FDA support for Major Depressive Disorder drug
AQ
07/23ALLERGAN : Receives FDA Fast Track Designation for AGN-241751 for the Treatment ..
PR
07/23ALLERGAN PLC : Wired News – Allergan’ and Molecular Partners’ Abicipar Meets Pri..
AC
07/23ALLERGAN : Pre-Market Research Reports on Generic Drugs Stocks -- Tricida, Zoeti..
PR
07/23ALLERGAN : Court denies appeal in Mohawk case, clarifies IPR's role
AQ
07/20ALLERGAN : AGN), Molecular Partners Announce Two Positive Phase 3 Clinical Trial..
AQ
07/20ALLERGAN : announce clinical trial success for abicipar
AQ
07/20ALLERGAN : abicipar pegol non-inferior to Lucentis, but increases inflammation
AQ
07/20ALLERGAN : Expands REFRESH® Portfolio With New REFRESH® REPAIR Lubricant Eye Dro..
AQ
07/20IRONWOOD PHARMACEUTICALS : Initiates Phase IIIb Study of Linaclotide in Adult Pa..
AQ
1  2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 15 533 M
EBIT 2018 7 411 M
Net income 2018 -1 106 M
Debt 2018 23 063 M
Yield 2018 1,49%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,55x
EV / Sales 2019 5,32x
Capitalization 63 160 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 212 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Charles Hugh-Jones Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC13.75%62 556
JOHNSON & JOHNSON0.59%375 479
PFIZER18.75%252 129
NOVARTIS-1.14%215 800
ROCHE HOLDING LTD.-4.00%212 015
MERCK AND COMPANY25.15%187 284